Nkarta Inc

NKTXNASDAQ · USD
2.75USD0.00 (-3.51%)
719

Nkarta Inc (NKTX) Wheel Strategy

NKTX wheel strategy scan found 1 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 86.9%.

Read more

Running a NKTX wheel strategy lets you generate consistent premium income on Nkarta Inc while setting your own entry and exit prices on the underlying. Nkarta Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own NKTX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best NKTX wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on NKTX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable NKTX wheel from a losing one.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.

The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the NKTX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your NKTX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Oct 16, 20262.50$0.05$0.13-0.292149%57.0%86.9%61

As of September 25, 2026

Run the Wheel on NKTX With Confidence

Find the best NKTX wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial